

The viral and non-viral vector manufacturing market, By Roots Analysis

The viral and non-viral vector manufacturing market, By Roots Analysis

LONDON, ENGLAND, UNITED KINGDOM, July 16, 2021 /EINPresswire.com/ -- The rapidly growing pipeline of genetically modified therapies reflects the surge in demand for high quality vectors, presenting lucrative opportunities for companies with the capabilities to manufacture viral and non-viral gene delivery solutions

London

Roots Analysis has announced the addition of "<u>Viral Vectors, Non-Viral</u> <u>Vectors and Gene Therapy</u> <u>Manufacturing</u> Market (4th Edition) 2021 – 2030" report to its list of offerings.


Over time, ~15 cell and gene therapies have been approved across the world. Since transgene delivery into biological producing cell lines, gene modified cell-

Example highlights

Presently, over 200 industry and non-industry players claim to have the necessary capabilities to manufacture different types of viral and non-viral vectors, for in-house requirements and / or contract service engagements
List of Vector and Gene Therapy Manufacturers



Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market



Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing

based therapies and the body, is an indispensable aspect of modern drug / therapy development efforts, high quality vectors are required by both medical researchers, drug developers and manufact7uring service providers, alike. In order to save time and costs, many stakeholders in the cell and gene therapy market have opted to outsource their vector manufacturing needs.

To order this 685+ page report, which features 170+ figures and 290+ tables, please visit <u>https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-</u>


<u>therapy-manufacturing-market-</u> /274.html

Key Market Insights

The market features the presence of over 225 industry players and nonindustry players It is currently dominated by the presence of mid-sized players (51-500 employees), which represent more than 55% of industry stakeholders, worldwide. Of these, ~80% are capable of synthesizing different types of viral vectors, and round 10% of the companies mentioned in the report claim to have expertise in manufacturing plasmid DNA.

Over the time, several new technology platforms have been developed to deal with existing production-related challenges

Majority (85%) of the available technologies are currently focused on viral vectors. The technology landscape analysis featured in the report, highlights the fact that 55% of the contemporary platforms are meant for the development and production of gene therapies.



Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Rootsanalysis



Close to 210 partnerships were inked in this market, over the last five years More than 55% of partnerships were inked post 2017, with the maximum activity being reported in 2020 (till September). Most of the deals (~27%) were manufacturing agreements, followed by product / technology licensing (24%), product development (17%) and R&D (9%) agreements.

Expansion activity in this domain has grown at a CAGR of 97%, between 2015 and 2020 Most of the reported expansions were related to the establishment of new facilities / plants (52%), followed by facility expansions (22%), indicative of the initiatives undertaken by service providers to cope with the rapidly increasing demand for good quality vectors.

The installed vector manufacturing capacity is estimated to be 63,000+ L

The majority share of the available vector manufacturing capacity belongs to companies with both clinical and commercial scale facilities (~70%). In fact, 65% of the estimated global vector producing capacity belongs to the larger and more established stakeholders in the market.

Till 2030, the annual demand for vectors is expected grow at an annualized rate of 21% Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2030, the demand, in terms of number of patients in need to interventions requiring some form of vector, is projected to be over 220,000.

The developed markets are likely to remain the major contributors, in terms of service revenues, to the market

The majority share of service revenues is anticipated to come from vector manufacturing project for oncological disorders (~55%). By 2030, the need for gene delivery solutions for commercialized therapies, is expected to be responsible for 60% of the annual service revenues, representing a CAGR of 39%.

To request a sample copy / brochure of this report, please visit <u>https://www.rootsanalysis.com/reports/274/request-sample.html</u>

Key Questions Answered

DWho are the leading players (contract service providers and in-house manufacturers) engaged in the development of vectors and gene therapies?

DWhich global regions are the considered as (contract) manufacturing hubs for vectors and gene therapies?

DWhat kind of technologies are used / being developed by stakeholders engaged in this domain?

What kind of companies are likely to partner with vector manufacturing service providers?
Which types of partnership models are commonly adopted by stakeholders in this industry?
What are the different types of expansions that have been undertaken by vector manufacturers?

DWhat are the emerging types of viral and non-viral vectors used in the manufacturing of genetically modified therapies?

Bow has the COVID-19 pandemic impacted the viral and non-viral vector, and <u>gene therapy</u> <u>manufacturing market</u>?

□What is the current, global demand for viral and non-viral vectors, and gene therapies? □⊞ow is the current and future market opportunity likely to be distributed across key market segments?

The USD 2.5+ billion (by 2030) financial opportunity associated with viral vector, non-viral vector and gene therapy manufacturing market has been analyzed across the following segments:

□□ab

□**ଘ**linical □**ଘ**ommercial

Image of VectorImage of Vector</

□Application Area □Gene Therapy □Cell Therapy □Vaccine

ITherapeutic Area
Dncological Disorders
Inflammation & Immunological Disorders
Neurological Disorders
Dphthalmic Disorders
Muscle Disorders
Metabolic Disorders
Cardiovascular Disorders
Dthers

Geographical Regions
North America
Burope
Asia-Pacific
MENA
Datin America and Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, the anticipated increase in demand for cell and gene therapies, is the most prominent driver of the growth of the vector supply market. The report includes detailed transcripts of discussions held with the following experts: DMenzo Havenga (Chief Executive Officer and President, Batavia Biosciences) Dicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals) Deffrey Hung (Chief Commercial Officer, Vigene Biosciences) Deficer Szpirer (Founder, Executive & Scientific Director, Delphi Genetics)

Divier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Ex-Business

Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)

Image: Alain Lamproye (Ex-President of Biopharma Business Unit, Novasep)

IJbost van den Berg (Ex-Director, Amsterdam BioTherapeutics Unit)

Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)

□Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes) □Colin Lee Novick (Managing Director, CJ Partners)

Bemyon Rubinchik (Scientific Director, ACGT)

DAstrid Brammer (Senior Manager Business Development, Richter-Helm)

DMarco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Ex-Marketing Manager, Plasmid Factory)

Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)

Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy)

INicolas Grandchamp (R&D Leader, GEG Tech)

The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), information related to its manufacturing facilities, proprietary vector manufacturing technology and an informed future outlook. **Advanced BioScience Laboratories Aldevron DAudentes** Therapeutics **BioReliance Brammer Bio** □Bluebird bio **DEmergent BioSolutions IBUJIFILM Diosynth Biotechnologies** □ MeiraGTx IMassBiologics □Spark Therapeutics □**V**igene Biosciences Biovian **DC**obra Biologics **DC**entre for Process Innovation **D**EinVector □Kaneka Eurogentec IIII IIII IIII **D**MolMed **D**rchard Therapeutics Dxford BioMedica

🛛 Richter-Helm

□Sanofi

□ŪniQure

IVibalogics
IVIVEbiotech
ICell and Gene Therapy Catapult
IVIVXi AppTec

For additional details, please visit

<u>https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-</u> <u>therapy-manufacturing-market-/274.html</u> or email sales@rootsanalysis.com

You may also be interested in the following titles:

1. Gene Therapies Market (4th Edition) by Therapeutic Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy and Others), Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas (Autoimmune Disorders, Cardiovascular Diseases, Genetic Disorders, Hematological Disorders, Metabolic Disorders, Muscle-related Diseases, Oncological Disorders, Ophthalmic Diseases and Others), Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

2. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition): Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, NHL, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma and Others), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100 and others), Key Players and Key Regions (North America, Europe, Asia Pacific, Latin America, MENA, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

3.Biopharmaceutical Contract Manufacturing Market (4th Edition) by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size (Small, Mid-sized, Large and Very Large), Biologics (Antibody, Vaccine, Cell Therapy and Other Biologics) and Key Geographical Regions (North America, Europe, Asia-Pacific, MENA and LATAM)- Industry Trends and Global Forecast to 2030 4.Iell and Gene Therapy CROs Market by Type of Therapy (Cell Therapy (Stem Cells, Immune Cells and Others) and Gene Therapy), Scale of Operation (Drug Discovery, Preclinical, Clinical and Commercialization), Preclinical Services Offered, Clinical Services Offered, and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (2nd Edition), 2021-2030

Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com

Gaurav Chaudhary Roots Analysis +1 415-800-3415 email us here

Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/546422094

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.